Navidea Biopharmaceuticals said enrollment has started for a Phase IIb trial that will test the safety and efficacy of its PET imaging agent NAV4694. The trial is meant to test whether the agent can detect amyloid plaque in patients with mild cognitive impairment and whether it can help pinpoint the patients likely to progress to Alzheimer's disease. Enrollment will take place at five U.S. locations.

Full Story:

Related Summaries